vs
梯瓦制药（TEVA）与惠而浦（WHR）财务数据对比。点击上方公司名可切换其他公司
梯瓦制药的季度营收约是惠而浦的1.1倍（$4.7B vs $4.1B），梯瓦制药净利率更高（10.2% vs 2.7%，领先7.5%），梯瓦制药同比增速更快（11.4% vs -0.9%），梯瓦制药自由现金流更多（$1.0B vs $989.0M），过去两年梯瓦制药的营收复合增速更高（11.1% vs -4.5%）
梯瓦制药工业有限公司是以色列跨国制药企业，核心业务聚焦仿制药研发生产，同时布局品牌药、药用活性成分（API）业务，也小范围开展合同生产服务及对外授权合作相关业务。
惠而浦是总部位于美国密歇根州本顿特许镇的跨国家电研发、生产及销售企业，位列《财富》世界500强。2023年集团年销售额约190亿美元，全球员工规模近5.9万人，在世界各地布局超55座生产及技术研发中心。
TEVA vs WHR — 直观对比
营收规模更大
TEVA
是对方的1.1倍
$4.1B
营收增速更快
TEVA
高出12.3%
-0.9%
净利率更高
TEVA
高出7.5%
2.7%
自由现金流更多
TEVA
多$27.0M
$989.0M
两年增速更快
TEVA
近两年复合增速
-4.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $4.7B | $4.1B |
| 净利润 | $481.0M | $109.0M |
| 毛利率 | 56.4% | 14.0% |
| 营业利润率 | 6.4% | 6.0% |
| 净利率 | 10.2% | 2.7% |
| 营收同比 | 11.4% | -0.9% |
| 净利润同比 | 321.7% | 127.8% |
| 每股收益（稀释后） | $0.42 | $1.92 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TEVAWHR
| Q4 25 | $4.7B | $4.1B | ||
| Q3 25 | $4.5B | $4.0B | ||
| Q2 25 | $4.2B | $3.8B | ||
| Q1 25 | $3.9B | $3.6B | ||
| Q4 24 | $4.2B | $4.1B | ||
| Q3 24 | $4.3B | $4.0B | ||
| Q2 24 | $4.2B | $4.0B | ||
| Q1 24 | $3.8B | $4.5B |
净利润TEVAWHR
| Q4 25 | $481.0M | $109.0M | ||
| Q3 25 | $433.0M | $73.0M | ||
| Q2 25 | $282.0M | $65.0M | ||
| Q1 25 | $214.0M | $71.0M | ||
| Q4 24 | $-217.0M | $-392.0M | ||
| Q3 24 | $-437.0M | $109.0M | ||
| Q2 24 | $-846.0M | $219.0M | ||
| Q1 24 | $-139.0M | $-259.0M |
毛利率TEVAWHR
| Q4 25 | 56.4% | 14.0% | ||
| Q3 25 | 51.4% | 14.7% | ||
| Q2 25 | 50.3% | 16.2% | ||
| Q1 25 | 48.2% | 16.8% | ||
| Q4 24 | 50.2% | 16.2% | ||
| Q3 24 | 49.6% | 16.1% | ||
| Q2 24 | 48.6% | 15.7% | ||
| Q1 24 | 46.4% | 14.3% |
营业利润率TEVAWHR
| Q4 25 | 6.4% | 6.0% | ||
| Q3 25 | 19.7% | 5.1% | ||
| Q2 25 | 10.9% | 5.4% | ||
| Q1 25 | 13.3% | 5.1% | ||
| Q4 24 | -0.7% | -3.3% | ||
| Q3 24 | -1.2% | 6.6% | ||
| Q2 24 | -0.1% | 3.3% | ||
| Q1 24 | -5.7% | -2.6% |
净利率TEVAWHR
| Q4 25 | 10.2% | 2.7% | ||
| Q3 25 | 9.7% | 1.8% | ||
| Q2 25 | 6.8% | 1.7% | ||
| Q1 25 | 5.5% | 2.0% | ||
| Q4 24 | -5.1% | -9.5% | ||
| Q3 24 | -10.1% | 2.7% | ||
| Q2 24 | -20.3% | 5.5% | ||
| Q1 24 | -3.6% | -5.8% |
每股收益（稀释后）TEVAWHR
| Q4 25 | $0.42 | $1.92 | ||
| Q3 25 | $0.37 | $1.29 | ||
| Q2 25 | $0.24 | $1.17 | ||
| Q1 25 | $0.18 | $1.28 | ||
| Q4 24 | $-0.19 | $-7.11 | ||
| Q3 24 | $-0.39 | $2.00 | ||
| Q2 24 | $-0.75 | $3.96 | ||
| Q1 24 | $-0.12 | $-4.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.6B | $669.0M |
| 总债务越低越好 | — | $6.2B |
| 股东权益账面价值 | $7.9B | $2.7B |
| 总资产 | $40.7B | $16.0B |
| 负债/权益比越低杠杆越低 | — | 2.26× |
8季度趋势，按日历期对齐
现金及短期投资TEVAWHR
| Q4 25 | $3.6B | $669.0M | ||
| Q3 25 | $2.2B | $934.0M | ||
| Q2 25 | $2.2B | $1.1B | ||
| Q1 25 | $1.7B | $1.0B | ||
| Q4 24 | $3.3B | $1.3B | ||
| Q3 24 | $3.3B | $1.1B | ||
| Q2 24 | $2.3B | $1.2B | ||
| Q1 24 | $3.0B | $1.2B |
总债务TEVAWHR
| Q4 25 | — | $6.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $6.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益TEVAWHR
| Q4 25 | $7.9B | $2.7B | ||
| Q3 25 | $7.3B | $2.6B | ||
| Q2 25 | $6.8B | $2.6B | ||
| Q1 25 | $6.3B | $2.6B | ||
| Q4 24 | $5.4B | $2.7B | ||
| Q3 24 | $6.1B | $3.0B | ||
| Q2 24 | $6.4B | $3.1B | ||
| Q1 24 | $7.3B | $2.4B |
总资产TEVAWHR
| Q4 25 | $40.7B | $16.0B | ||
| Q3 25 | $39.9B | $16.9B | ||
| Q2 25 | $40.1B | $16.8B | ||
| Q1 25 | $38.4B | $16.5B | ||
| Q4 24 | $39.3B | $16.3B | ||
| Q3 24 | $41.8B | $17.2B | ||
| Q2 24 | $41.3B | $17.3B | ||
| Q1 24 | $42.8B | $17.4B |
负债/权益比TEVAWHR
| Q4 25 | — | 2.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.2B | $1.1B |
| 自由现金流经营现金流 - 资本支出 | $1.0B | $989.0M |
| 自由现金流率自由现金流/营收 | 21.6% | 24.1% |
| 资本支出强度资本支出/营收 | 3.0% | 3.7% |
| 现金转化率经营现金流/净利润 | 2.41× | 10.45× |
| 过去12个月自由现金流最近4个季度 | $1.1B | $81.0M |
8季度趋势，按日历期对齐
经营现金流TEVAWHR
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | $369.0M | $33.0M | ||
| Q2 25 | $227.0M | $19.0M | ||
| Q1 25 | $-105.0M | $-721.0M | ||
| Q4 24 | $575.0M | $1.1B | ||
| Q3 24 | $693.0M | $214.0M | ||
| Q2 24 | $103.0M | $388.0M | ||
| Q1 24 | $-124.0M | $-873.0M |
自由现金流TEVAWHR
| Q4 25 | $1.0B | $989.0M | ||
| Q3 25 | $233.0M | $-52.0M | ||
| Q2 25 | $131.0M | $-63.0M | ||
| Q1 25 | $-232.0M | $-793.0M | ||
| Q4 24 | $446.0M | $970.0M | ||
| Q3 24 | $545.0M | $127.0M | ||
| Q2 24 | $6.0M | $275.0M | ||
| Q1 24 | $-248.0M | $-988.0M |
自由现金流率TEVAWHR
| Q4 25 | 21.6% | 24.1% | ||
| Q3 25 | 5.2% | -1.3% | ||
| Q2 25 | 3.1% | -1.7% | ||
| Q1 25 | -6.0% | -21.9% | ||
| Q4 24 | 10.5% | 23.5% | ||
| Q3 24 | 12.6% | 3.2% | ||
| Q2 24 | 0.1% | 6.9% | ||
| Q1 24 | -6.5% | -22.0% |
资本支出强度TEVAWHR
| Q4 25 | 3.0% | 3.7% | ||
| Q3 25 | 3.0% | 2.1% | ||
| Q2 25 | 2.3% | 2.2% | ||
| Q1 25 | 3.3% | 2.0% | ||
| Q4 24 | 3.1% | 3.3% | ||
| Q3 24 | 3.4% | 2.2% | ||
| Q2 24 | 2.3% | 2.8% | ||
| Q1 24 | 3.2% | 2.6% |
现金转化率TEVAWHR
| Q4 25 | 2.41× | 10.45× | ||
| Q3 25 | 0.85× | 0.45× | ||
| Q2 25 | 0.80× | 0.29× | ||
| Q1 25 | -0.49× | -10.15× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.96× | ||
| Q2 24 | — | 1.77× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
WHR
| Refrigeration | $1.2B | 30% |
| Laundry | $1.1B | 27% |
| Cooking | $1.1B | 26% |
| Dishwashing | $299.0M | 7% |
| Other | $266.0M | 6% |
| Spare Parts And Warranties | $139.0M | 3% |
